相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。131I-Meta-iodobenzylguanidine followed by busulfan and melphalan and autologous stem cell rescue in high-risk neuroblastoma
Stefano Giardino et al.
PEDIATRIC BLOOD & CANCER (2021)
Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with 131I-MIBG therapy for high-risk neuroblastoma
Jin Kyung Suh et al.
PEDIATRIC TRANSPLANTATION (2020)
Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
Hiroshi Wakabayashi et al.
DIAGNOSTICS (2020)
Neuroblastoma - A Neural Crest Derived Embryonal Malignancy
John Inge Johnsen et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma
Elzbieta Wawrzyniak-Dzierzek et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma
Toni Illhardt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Theranostic radiopharmaceuticals: established agents in current use
James R. Ballinger
BRITISH JOURNAL OF RADIOLOGY (2018)
Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience
Isabelle Ferry et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2018)
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2018)
Current Consensus on I-131 MIBG Therapy
Daiki Kayano et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRYAND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS
Olivier Cougnenc et al.
RADIATION PROTECTION DOSIMETRY (2017)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
Ruth Ladenstein et al.
LANCET ONCOLOGY (2017)
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine
Kelly E. Huibregtse et al.
EUROPEAN JOURNAL OF CANCER (2016)
Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients
Ashley Teusink et al.
TRANSFUSION (2016)
131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study
Gregory A. Yanik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF
A. A. Maschan et al.
BONE MARROW TRANSPLANTATION (2015)
Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG)
Margaret J. Zhou et al.
EUROPEAN JOURNAL OF CANCER (2015)
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Navin R. Pinto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma
S. C. Clement et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
A systematic review of 131 I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
Jayne S. Wilson et al.
EUROPEAN JOURNAL OF CANCER (2014)
Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study
Boris Decarolis et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma
Sarah French et al.
PEDIATRIC BLOOD & CANCER (2013)
I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma
Jigang Yang et al.
NUCLEAR MEDICINE COMMUNICATIONS (2012)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry
Alberto Garaventa et al.
EUROPEAN JOURNAL OF CANCER (2009)
EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy
Francesco Giammarile et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines
Claudia Lanvers-Kaminsky et al.
ANTI-CANCER DRUGS (2006)
Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma
M Miano et al.
BONE MARROW TRANSPLANTATION (2001)
分享论文
